Fred Hutch’s Dr. Eric Holland collaborates with Dana-Farber on promising mouse study
Feb. 6, 2014
| By Kristen Woodward
An altered radiation treatment schedule for the most common and lethal form of brain cancer has been shown to extend the survival period of mice with the disease, which suggests that some alteration in schedule may be able to do the same for human patients.
Hans-Peter Kiem and colleagues find chemo-resistant genes may enable safer, more effective treatment for brain cancer patients
May 23, 2011
| By Dean Forbes
Chemotherapy kills cancer cells, but its toxic effects on normal cells such as bone marrow and blood cells limits its use. Fred Hutchinson Cancer Research Center researchers have found a possible approach to reduce this toxicity: modify the bone marrow cells with a gene that makes them resistant to chemotherapy.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.